Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03523585
Title DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Daiichi Sankyo, Inc.
Indications

Her2-receptor positive breast cancer

Therapies

Trastuzumab deruxtecan

Capecitabine + Lapatinib

Capecitabine + Trastuzumab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL


No variant requirements are available.